AINIA / Quality and Safety / Omics studies of biomarkers

Discovery and study of biomarkers using omics technologies

Advanced multi-omics analysis and data integration for biomarker Discovery and characterisation

Need for advanced solutions for biomarker identification

In a context where personalised medicine, early prevention and therapeutic efficiency have become global priorities, demand for omics studies for biomarker identification is growing rapidly.

The pharmaceutical, biotechnology, food and clinical sectors are increasingly seeking tools capable of offering a deep and multi-capability understanding of biological systems. Technologies such as genomics, transcriptomics, proteomics and metabolomics make it possible to detect predictive, diagnostic and prognostic molecular signatures with unprecedented precision.

Our solution

Comprehensive solution

To respond to the growing market demand for omics studies, we offer a comprehensive solution based on state-of-the-art technologies.

Advanced technologies

Our laboratory combines high-throughput sequencing platforms (NGS) with high-resolution mass spectrometry (LC-HRMS/MS), enabling in-depth and simultaneous analysis of:

Genomic variations.
Protein profiles.
Relevant metabolomic signatures.

Multi-capability perspective

This multi-capability approach provides a comprehensive view of the biological state of complex systems, which is key to the robust identification of diagnostic, prognostic and functional biomarkers.

Bioinformatics infrastructure

In addition, our bioinformatics infrastructure is designed to process large volumes of data, integrate different omics levels and extract relevant information.

From data to decisions

This approach makes it possible to transform complex data into interpretable results geared towards decision-making.

Impact on R&D and other contexts

We accelerate R&D processes, reduce uncertainty and add value in clinical, industrial and biotechnology contexts.

Applications

Impact and benefits

Increased strategic value of R&D through decisions based on molecular evidence
Significant reduction in time and costs through integrated omics data
Greater precision in the development and validation of biotechnology products
Improved competitiveness and differentiation thanks to robust biomarkers

Innovation and biomarkers

The application of omics studies for biomarker discovery has represented a qualitative leap in our innovation capacity. We have succeeded in detecting differential biomarkers with high strategic value, scientifically supporting our decisions and strengthening the competitiveness of our products and processes.

Would you like to know more?

Leave us your details and we will contact you to answer your questions or continue the conversation.

Elias Hurtado

Omics studies

Name

Surname

Company

Phone

Country

Province

Message

I consent to the use of my personal data to process my request, as established in its Privacy Policy.

I consent to the use of my data to receive information and commercial communications from your entity.

Basic information on data protection

Controller

AINIA

Address

Calle Benjamín Franklin, 5 a 11, CP 46980 Paterna (Valencia)

Purpose

To process, record and contact you to resolve the request you make through this contact form

Legal basis

Your data will be processed only with your consent, by ticking the box shown in this form

Recipients

Your data will not be shared with third parties

Rights

You have the right to request access to your data, correct or delete it, you may also request restriction of its processing, object to it and to the portability of your data, by contacting our postal address or [email protected]

More information

You can find more information in our Privacy Policy

DPD

If you have any questions about how we will process your data or wish to submit a suggestion or complaint, contact the Data Protection Officer at [email protected] or via the data subject request form